Li B, et al. - The authors sought to develop a robust, individualized immune signature that could estimate prognosis in patients with early-stage nonsquamous non–small cell lung cancer (NSCLC). As per findings, the proposed clinical-immune signature seemed a promising biomarker for estimating overall survival in nonsquamous NSCLC, including early-stage disease. they recommended prospective studies to test the clinical utility of the biomarker in individualized management of nonsquamous NSCLC.